TRPM8 and posterior cortical atrophy: In conclusion, our study together with the recently published high-resolution molecular structure of TRPM859,60, the development of TRPM8 agonists with improved pharmacological characteristics61, and innovative methods to deliver TRPM8 agonists to PCa cells62, support the design of preclinical in vivo trials for testing safety63 and efficacy of TRPM8 activation as a novel strategy for a more effective treatment of locally advanced/high-risk PCa patients, an oncologic population with urgent unmet needs.